THE COMMUNITY ONCOLOGY ALLIANCE documented an 82 percent increase in cancer clinic closings and a 143 percent increase in consolidation into hospitals in a new report since its first in 2010, which reported on activity from 2008 to 2010.
Last week, FDA granted accelerated approval to Replimune Group Inc. for it’s biologic, RP1 (vusolimogene oderparepvec), following the FDA Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.
